Symproic Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(2 years from now)

US8536192 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(2 years from now)

US8084460 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(3 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(7 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(8 years from now)



Symproic is a drug owned by Biodelivery Sciences International Inc. It is used for treating opioid-induced constipation. Symproic uses Naldemedine Tosylate as an active ingredient. Symproic was launched by Bdsi in 2017. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 13, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 23, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: 23 March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET

More Information on Dosage

SYMPROIC family patents

Family Patents